Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Twinpigbiolab Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter represents the active prosecution focus for the company. The emphasis on Biotechnology & Pharmaceuticals suggests that the intellectual property involves pharmaceutical or biological research. Practitioners should prepare for the specific examination standards common in this technology area.
The pending office action is assigned to 1 distinct examiner and a distinct art unit. Having the action reviewed by a distinct examiner within 1 distinct art unit provides a streamlined prosecution path. This lack of departmental diversity means that the applicant can focus on the specific guidelines of a single art unit. Such centralization often results in a more predictable examination timeline.
AFREMOVA, VERA is the busiest examiner, responsible for the busiest examiner pending action. As the only examiner currently assigned to the portfolio, AFREMOVA, VERA serves as the primary point of contact for the company's pending matters. This allows for the development of a consistent rapport between the practitioner and the examiner. Resolving the pending office action will require addressing the specific technical concerns raised by AFREMOVA, VERA within the identified art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837001 | COMPOSITION FOR PREVENTION AND TREATMENT OF MUSCLE DISEASE, CONTAINING MAGNOLIA OFFICINALIS EXTRACT AS ACTIVE INGREDIENT | AFREMOVA, VERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837001 | COMPOSITION FOR PREVENTION AND TREATMENT OF MUSCLE DISEASE, CONTAINING MAGNOLIA OFFICINALIS EXTRACT AS ACTIVE INGREDIENT | AFREMOVA, VERA | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837001 | COMPOSITION FOR PREVENTION AND TREATMENT OF MUSCLE DISEASE, CONTAINING MAGNOLIA OFFICINALIS EXTRACT AS ACTIVE INGREDIENT | AFREMOVA, VERA | 1655 | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial